Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/8/2026


Go back to Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group

FBR Capital Remains Bullish as Prima BioMed (PBMD) Announces Investigator-Sponsored Trial

July 12, 2016 1:47 PM UTC

FBR Capital reiterated an Outperform rating and $6.00 price target on Prima Biomed (NASDAQ: PBMD) following the company's announced collaboration for an investigator-sponsored clinical trial.

Analyst Vernon Bernardino commented, "Earlier today, July 12, Prima BioMed (PBMD) announced a new collaboration for an investigatorsponsored clinical trial named INSIGHT to evaluate intra-tumoral injection of PBMDs immune-oncology therapy,... More